Shield Therapeutics Management
Management criteria checks 3/4
Shield Therapeutics' CEO is Anders Lundstrom, appointed in Jul 2024, has a tenure of 1.58 years. directly owns 0.055% of the company’s shares, worth $79.21K. The average tenure of the management team and the board of directors is 2.8 years and 5.2 years respectively.
Key information
Anders Lundstrom
Chief executive officer
US$154.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.05% |
| Management average tenure | 2.8yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
CEO
Anders Lundstrom (63 yo)
Mr. Anders Lundstrom has been its Chief Executive Officer and Executive Director since February 1, 2025 and was an Interim Chief Executive Officer of Shield Therapeutics plc since July 24, 2024 until Febru...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 1.6yrs | US$154.00k | 0.055% $ 79.2k | |
| Co-Founder & Non Executive Director | 18.1yrs | US$51.00k | 1.09% $ 1.6m | |
| Chief Financial Officer | 2.1yrs | no data | no data | |
| General Counsel | 8.4yrs | no data | no data | |
| Group HR Director | no data | no data | no data | |
| Head of Pharmacovigilance & Medical Information | no data | no data | no data | |
| Chief Commercial Officer | 2.8yrs | no data | no data | |
| Senior Director of People & Culture | no data | no data | no data |
Experienced Management: SHIE.F's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4.8yrs | US$154.00k | 0.055% $ 79.2k | |
| Co-Founder & Non Executive Director | 5.7yrs | US$51.00k | 1.09% $ 1.6m | |
| Independent Non Executive Chairman | 7.6yrs | US$128.00k | 0.51% $ 744.6k | |
| Non-Executive Director | 1.6yrs | US$25.00k | no data | |
| Independent Vice Chairman | 10yrs | US$61.00k | 0.017% $ 24.1k | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 4.8yrs | US$51.00k | 0.025% $ 36.8k | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Notable Scientific Advisory Board | no data | no data | no data |
Experienced Board: SHIE.F's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/06 15:08 |
| End of Day Share Price | 2026/02/02 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shield Therapeutics plc is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Howard Miller | Canaccord Genuity |
| Mark Brewer | Cavendish |
| Michael Mitchell | Cavendish |